Recordati Acquires Sanofi's Enjaymo for $825M to Boost Rare Disease Portfolio

Recordati has reached an agreement to acquire Sanofi's global rights to Enjaymo, a biologic drug for rare diseases, for $825 million upfront, along with up to $250 million in potential milestone payments. Enjaymo is notable as the only FDA-approved treatment for hemolysis in cold agglutinin disease (CAD) patients, with approvals also in Europe and Japan[1][2]. This deal significantly bolsters Recordati’s presence in the rare disease market across key regions, with expectations of expanding its revenue stream starting in 2025[1]. Enjaymo's sales are forecasted to reach €150 million by 2025 and potentially €250-300 million at peak levels. The agreement, set to be finalized by the end of 2024, aligns with Recordati’s strategic goals of enhancing its focus on rare diseases[2].